Craneware Delivers Solid H1 Growth and Cash Generation Despite US Rebate Programme Disruption

Craneware ( (GB:CRW) ) just unveiled an announcement.

Craneware reported a solid first half for FY26, with revenue for the six months to 31 December 2025 rising 6% year-on-year to about $106m and adjusted EBITDA growing at a double-digit rate to roughly $33.4m, supported by sustained demand across its core markets and annual recurring revenue up around 4% to $184.3m. Strong cash generation enabled the group to reduce bank debt to $23.4m while maintaining cash reserves of $71.2m, and management said trading remains in line with expectations for the year to June 2026, underpinned by a robust sales pipeline and a high proportion of recurring revenue. Although the temporary halt of the US HRSA Rebate Model Pilot weighed on reported revenue and ARR in the period, Craneware’s rapid deployment of a rebate solution for affected customers highlighted the depth of its Trisus platform and reinforced its positioning as a key independent data and insights provider at the centre of the US healthcare market, supporting its ambition for near-term double-digit growth.

The most recent analyst rating on (GB:CRW) stock is a Hold with a £2223.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

Spark’s Take on GB:CRW Stock

According to Spark, TipRanks’ AI Analyst, GB:CRW is a Neutral.

Craneware’s overall stock score reflects strong financial performance and positive corporate events, which are offset by technical indicators suggesting bearish momentum and a high valuation. The company’s strategic initiatives and solid balance sheet are significant strengths, but the high P/E ratio and current market trends present challenges.

To see Spark’s full report on GB:CRW stock, click here.

More about Craneware

Craneware plc is a UK-listed provider of healthcare financial performance and operational transformation solutions, focused primarily on the US healthcare market. Through its Trisus cloud ecosystem, the company delivers data-driven revenue and margin intelligence, advanced analytics and chargemaster management tools that help hospitals and healthcare organisations optimise financial performance and improve sustainability. Leveraging long-standing sector expertise and partnerships with technology leaders such as Microsoft and Oracle, Craneware positions itself as a strategic partner to providers navigating the complexities of healthcare finance and reimbursement.

Average Trading Volume: 77,906

Technical Sentiment Signal: Hold

Current Market Cap: £687.2M

Learn more about CRW stock on TipRanks’ Stock Analysis page.